Evidence map›Paper›PMID 30819246›Full record

ArticleStem cell research & therapy2019

A novel approach to label bone marrow-derived mesenchymal stem cells with mixed-surface PAMAM dendrimers.

Nikolas Munro, Bhairavi Srinageshwar, Firas Shalabi, Maria Florendo, Paulina Otero, Cassandra Thompson, Jordyn Kippe, Clayton Malkowski, Sydney Climie, Andrew N Stewart and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nikolas MunroCollege of Medicine, Central Michigan University, Mount Pleasant, MI, USA.
Bhairavi SrinageshwarCollege of Medicine, Central Michigan University, Mount Pleasant, MI, USA.
Firas ShalabiCollege of Medicine, Central Michigan University, Mount Pleasant, MI, USA.
Maria FlorendoCollege of Medicine, Central Michigan University, Mount Pleasant, MI, USA.
Paulina OteroField Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.
Cassandra ThompsonField Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.
Jordyn KippeProgram in Neuroscience, Central Michigan University, Mount Pleasant, MI, USA.
Clayton MalkowskiField Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.
Sydney ClimieField Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.
Andrew N StewartField Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.
Rachel KimCollege of Medicine, Central Michigan University, Mount Pleasant, MI, USA.
Joseph ZhouCollege of Medicine, Central Michigan University, Mount Pleasant, MI, USA.
Douglas SwansonDepartment of Chemistry & Biochemistry, Central Michigan University, Mount Pleasant, MI, USA.
Gary L DunbarField Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.
Ajit SharmaDepartment of Chemistry & Biochemistry, Central Michigan University, Mount Pleasant, MI, USA.
Julien RossignolCollege of Medicine, Central Michigan University, Mount Pleasant, MI, USA. rossi1j@cmich.edu.ORCID 0000-0002-8662-0547

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTransplantation of mesenchymal stem cells has created enormous opportunities as a potential treatment for various diseases including neurodegenerative diseases. Given current techniques, such as Hoechst labeling, have safety and leakage issues, our study focused, as a proof-of-concept, on a new dendrimer-based technique for labeling these stem cells to ensure their efficacy and safety following transplantation into the brain of a healthy mice. METHODS AND

resultsThe bone marrow-derived mesenchymal stem cells (BM-MSCs) were labeled using polyaminoamine (PAMAM) dendrimers following which their stemness based on their proliferation and differentiation ability were analyzed by gold standard methods. These labeled BM-MSCs were transplanted into the striatum of C57BL/6J mice and were tracked using in vivo imaging system (IVIS) and analyzed using tissue imaging, 2 weeks after transplantation. Our results showed that the dendrimer-labeled BM-MSCs were able to successfully maintain their stemness and were tracked in vivo following transplantation. Unlike Hoechst, we did not find the dendrimers to be leaking out of the cells and were very specific to the cells that up took the dendrimers. Moreover, no adverse events were found in the transplanted animals proving that this is a safer method.

conclusionsLabeling BM-MSCs using fluorescently tagged PAMAM dendrimers can be used as a potentially safe and efficient method for labeling cells, particularly stem cells, in vitro and in vivo following transplantation in rodents.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsCell DifferentiationCell TrackingDendrimersIntravital MicroscopyMesenchymal Stem CellsMiceMolecular ImagingStaining and LabelingDendrimersPAMAM StarburstCell labeling techniqueCell transplantationHoechstImagingMesenchymal stem cellsPAMAM dendrimer nanoparticles

Identifiers

PMID30819246
PMCPMC6393977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.